On­coRe­sponse wraps Se­ries A with $22.5M; Plot­ting IPO, BerGen­Bio part­ners with Mer­ck on can­cer com­bos

→ The im­muno-on­col­o­gy an­ti­body dis­cov­ery com­pa­ny On­coRe­sponse, cre­at­ed by MD An­der­son and Ther­a­clone Sci­ences, just com­plet­ed a long-run­ning Se­ries A with $22.5 mil­lion. The biotech has been piec­ing this to­geth­er for awhile now. Most re­cent­ly in­sid­ers and HT Fam­i­ly Of­fice con­tributed to the round, fol­low­ing Bax­al­ta (now Shire), Great­Point Ven­tures, the Helsinn In­vest­ment Fund, Arch Ven­ture Part­ners, Canaan Part­ners, and MD An­der­son, with William Marsh Rice Uni­ver­si­ty and Alexan­dria Re­al Es­tate Eq­ui­ties al­so par­tic­i­pat­ing. “With the fi­nal clos­ing of our Se­ries A, we look ahead to the con­tin­ued de­vel­op­ment of our re­search pro­grams that aim to ex­pand the promise of im­muno-on­col­o­gy by iden­ti­fy­ing ther­a­peu­ti­cal­ly rel­e­vant an­ti­bod­ies from pa­tients with elite re­sponse to can­cer im­munother­a­py in a num­ber of on­col­o­gy in­di­ca­tions,” said CEO Clif­ford Stocks.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.